Focus

Our focus at Flynn Pharma is on prescription pharmaceutical products. We acquire under-promoted brands from other pharmaceutical companies, who often have numerous products that are too small for them, or are no longer of strategic importance and are not given any priority.

Further, we license late stage development products from R&D companies in specialist areas such as antibiotics, drugs affecting the Central Nervous System, oncology and adjunctive therapies.

Flynn has licensed in and successfully launched Medikinet XL (sustained release methylphenidate) and Depodur.

Flynn would be interested in hearing from other overseas companies who are looking to market their brands in Europe.